Article citationsMore >>

Sié, P., Samama, C.M., Godier, A., Rosencher, N., Steib, A., Llau, J.V., Van der Linden, P., Pernod, G., Lecompte, T., Gouin-Thibault, I., and Albaladejo, P., Working Group on Perioperative Haemostasis; French Study Group on Thrombosis and Haemostasis, Archives of Cardiovascular Diseases, 104(12). 669-676. December 2011.

has been cited by the following article:

Article

A Case of Periprocedural Discontinuation of Apixaban Resulting in Intra-aortic Thrombosis

1Division of Cardiology, Department of Internal Medicine, State University of New York, Downstate Medical Center, Brooklyn, New York, U.S.A.

2Department of Internal Medicine, State University of New York, Downstate Medical Center, Brooklyn, New York, U.S.A.


American Journal of Medical Case Reports. 2016, Vol. 4 No. 1, 16-18
DOI: 10.12691/ajmcr-4-1-5
Copyright © 2016 Science and Education Publishing

Cite this paper:
Sabu John, Pramod Theetha Kariyanna, Jonathan Marmur, Kamal Preet Singh, Mary Mallappallil. A Case of Periprocedural Discontinuation of Apixaban Resulting in Intra-aortic Thrombosis. American Journal of Medical Case Reports. 2016; 4(1):16-18. doi: 10.12691/ajmcr-4-1-5.

Correspondence to: Pramod  Theetha Kariyanna, Department of Internal Medicine, State University of New York, Downstate Medical Center, Brooklyn, New York, U.S.A.. Email: drtkpram@gmail.com

Abstract

Apixaban, a novel oral anticoagulant is approved for anticoagulation in non-valvular atrial fibrillation. Apixaban is found to be superior to warfarin in prevention of stroke and thromboembolism and is associated with lesser risk of bleeding. Peri-procedural discontinuation of apixaban is safe, but the risk of thrombosis exists. We here present a case of arterial thrombosis that lead to lower limb ischemia upon periprocedural discontinuation of apixaban.

Keywords